Skip to content
OpenCapital
Get started

Organon OGN Marvelon/Mercilon — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Mirum Pharmaceuticals, Inc. logo
MIRMLivmarli — Product sales, net
$113.8M+55.4%
Eli Lilly logo
LLYVerzenio — Revenue
$1.3B+12.3%
Pfizer logo
PFELorbrena — Revenues:
$305M+37.4%
Eli Lilly logo
LLYMounjaro — Revenue
$8.66B+125%
Incyte logo
INCYMINJUVI/MONJUVI — Total revenues
$49.23M+66.6%
Bristol-Myers Squibb logo
BMYRevlimid — Total Revenues
$349M-62.7%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's marvelon/mercilon — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's marvelon/mercilon — revenue?
Organon (OGN) reported marvelon/mercilon — revenue of $26M in Q1 2026.
How has Organon's marvelon/mercilon — revenue changed year-over-year?
Organon's marvelon/mercilon — revenue decreased by 33.3% year-over-year, from $39M to $26M.
What is the long-term trend for Organon's marvelon/mercilon — revenue?
Over 4 years (2021 to 2025), Organon's marvelon/mercilon — revenue has grown at a 6.7% compound annual growth rate (CAGR), from $98M to $127M.
What does marvelon/mercilon — revenue mean?
This metric represents the total annual net sales generated by the Marvelon and Mercilon product line within the women's health portfolio. It reflects the market demand and commercial performance of these specific oral contraceptive brands across global markets. Tracking this revenue stream helps investors assess the stability and lifecycle maturity of the company's established women's health assets.